Marketing

Pfizer, BioNTech win EU vaccine approval as UK grapples with new coronavirus variant

In a press conference on the authorization, BioNTech CEO Ugur Sahin expressed confidence the vaccine would protect against the emerging virus variant in the U.K.

By Ned Pagliarulo • Dec. 22, 2020

Sponsored by IQVIA

The role of optimized omnichannel marketing in a challenging environment

How can pharma marketers overcome today's cost-constrained, competitive environment?

Hospitals start coronavirus vaccinations in sweeping, nationwide effort

A New York nurse was among the first to get the shot after FDA authorization last week. Many other health systems are either preparing to receive supplies or are already beginning immunizations.

By Samantha Liss • Dec. 14, 2020

UK drug regulator is first to clear Pfizer, BioNTech's coronavirus vaccine

The approval is a notable milestone in the historic pursuit of a protective shot for COVID-19. The two drugmakers plan to ship the first doses within days.

By Jonathan Gardner • Dec. 02, 2020

CDC panel recommends giving first coronavirus vaccines to healthcare workers, nursing home residents

Advisers on the CDC panel cited risk and disease burden as reasons for setting their priority list for the first vaccine doses to become available, supply of which will be extremely limited.

By Jonathan Gardner • Dec. 01, 2020

Deep Dive

Hospitals scramble to get ready for coronavirus vaccines

Facilities are preparing ultra-cold storage capabilities and reviewing security plans as they brace for their role in distributing potentially multiple shots.

By Shannon Muchmore • Nov. 19, 2020

As US cases surge, FDA clears first fully at-home COVID-19 test

The prescription test from Lucira Health can deliver results within 30 minutes, and could help boost U.S. testing capacity. Some experts, however, called for more guidance on proper use.

By Greg Slabodkin • Nov. 18, 2020

Copycat to top-selling eye drug takes a step toward market

The FDA is reviewing Samsung Bioepis and Biogen's biosimilar of Lucentis. If approved, it would be the first biosimilar for an eye disease drug.

By Kristin Jensen • Nov. 18, 2020

Sponsored by IQVIA

Finding the right mix: Digital transformation offers opportunities for improved HCP engagement

Field teams and HCPs alike are learning how digital, data-driven approaches can best support safe, productive engagement.

Trump administration to require insurers cover coronavirus vaccines

Late-stage vaccine results are expected soon from Pfizer and Moderna, putting pressure on the Trump administration to put in motion plans for what's likely to be a complex and challenging distribution process.

By Shannon Muchmore • Oct. 29, 2020

EQRx builds cancer drug pipeline as plans to challenge big pharma take shape

The startup, which aims to develop lower-cost alternatives to branded medicines, has licensed two drugs from CStone Pharmaceuticals in a deal that could signal a coming price war in cancer immunotherapy.

By Kristin Jensen • Oct. 27, 2020

Facing vaccine doubts, US grapples with building confidence in coronavirus shots

The CDC, for example, doesn't support vaccine mandates for healthcare workers or essential employees, an agency official told experts convened by the FDA last week.

By Jonathan Gardner • Oct. 22, 2020

Purdue, reaching $8B settlement with US, pleads guilty to charges over opioid sales

Under a deal reached with the Department of Justice, Purdue faces fines and a forfeiture worth more than $5 billion — the largest penalties ever for a drug company.

By Jacob Bell • Oct. 21, 2020

Sponsored by Veeva Crossix

Doctors are consumers too! How DTC media impacts HCPs

The findings have implications for how pharma teams should think about their DTC and HCP efforts — they are no longer two separate marketing channels.

Nestlé​ makes newly acquired Aimmune a stand-alone unit, appoints new CEO

Andrew Oxtoby, formerly chief commercial officer at the peanut allergy drugmaker, will take over as head of the new Nestlé business.

By Kristin Jensen • Oct. 14, 2020

FDA moves to pull preterm birth drug from market

AMAG Pharma, the maker of Makena, said the company disagreed with the FDA's proposal and plans to evaluate its options following a failed study.

By Kristin Jensen • Oct. 07, 2020

Sponsored by IQVIA

Achieving success in pharma marketing: The need for a personalized, omnichannel approach

Personalized, insight-driven omnichannel marketing has never been more beneficial or important. 

After setback in the US, Galapagos' main drug finds success elsewhere

A month after the FDA surprisingly rejected the rheumatoid arthritis drug, called filgotinib, it's been cleared by regulators in Europe and Japan.

By Jacob Bell • Sept. 28, 2020

Health insurer sues Indivior over 'profit protection scheme'

Centene aims to recoup money it paid for Indivior's Suboxone product, alleging the drugmaker devised a plan to box out generic competitors.

By Samantha Liss • UPDATED: Sept. 23, 2020 at 11:47 a.m.

Cigna rebrands health services division, including Express Scripts, as Evernorth

The change, which has been in the works since before the pandemic, is the next step in integrating the companies' business since their merger in 2018.

By Rebecca Pifer • Sept. 16, 2020

Hospitals urge HHS to step in on 340B fight with drugmakers

The dispute stems from drugmakers deciding to stop giving 340B discounts to contract pharmacies, which many hospitals use.

By Shannon Muchmore • Sept. 09, 2020

Thermo Fisher deal for Qiagen falls apart after companies fail to secure investor backing

Thermo Fisher had raised its bid for Qiagen to about $12.5 billion, but less than half of the company's shares were tendered by the offer's expiration Monday.

By Nick Paul Taylor , Maria Rachal , Greg Slabodkin • UPDATED: Aug. 13, 2020 at 11:39 a.m.

Bristol Myers pledges to spend $300M on addressing racial, health disparities

The drugmaker aims to double Black and Latinx representation in its executive ranks, among other commitments.

By Kristin Jensen • Aug. 12, 2020

First liquid biopsy test that uses advanced gene sequencing approved by FDA

The test, developed by Guardant Health, combines next-generation sequencing with a cancer blood test.

By Susan Kelly • Aug. 10, 2020

Amarin decides to go it alone in Europe, as uncertainty clouds heart drug's US future

Chief executive John Thero said the company decided against "multiple proposals" for sales partnerships on Vascepa in Europe. Doing so, however, keeps the pressure on Amarin to deliver.

By Ben Fidler • Aug. 04, 2020